|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The homeobox transcription factor PROX1 is induced by high Wnt/β-catenin activity in intestinal adenomas and colorectal cancer, where it promotes tumor progression.
|
30154153 |
2018 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The HNF-1α-mutated and inflammatory adenoma subgroups are more commonly seen in association with the OCP whereas there is an increased incidence of the β-catenin positive subtype with anabolic steroid use.
|
30955069 |
2019 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The frequent observation of constitutive activation of Wnt signaling due to loss-of-function mutations in the tumor suppressor gene APC or gain-of-function mutation in β-catenin in both adenomas and carcinomas, suggests perhaps that the Wnt pathway serves an early or initiating insult in the oncogenic process.
|
22266195 |
2012 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The clinical, pathological, and immunophenotypic (hMLH1, hMSH2, MGMT, MIB-1, p53, and beta-catenin) properties of 28 mixed hyperplastic and adenomatous polyps of the colon (7 of which also contained carcinoma within the same lesion) were evaluated for the above immunopeptides in each of the different morphologic areas of the polyps, and the results were compared to traditional hyperplastic polyps, serrated adenomas, and conventional (nonserrated) adenomas.
|
15712188 |
2005 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Successive increases in the expression of ctnnb1 (beta-catenin) from normal to tubular adenomas to villous adenomas was seen.
|
20514431 |
2010 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Subsequent Northern blotting, real-time reverse transcription-PCR, and in situ hybridization analysis confirmed their induction in beta-catenin-activated epithelial cells of murine adenomas.
|
16488993 |
2006 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Somatic mutations of β-catenin and PRKACA are observed in non secreting or cortisol producing adenomas, respectively.
|
26038203 |
2015 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Small adenomas with beta-catenin mutations do not appear to be as likely to progress to larger adenomas and invasive carcinomas as other adenomas, however, with the result that beta-catenin mutations are only rarely seen in invasive cancers.
|
10197610 |
1999 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Similar to sporadic CRC, CTNNB1 was frequently activated at the adenoma stage, and TP53 mutation occurred during cancer development from adenoma.
|
27563825 |
2016 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Sequencing of genomic DNA extracted from a subset of hyperplastic polyps, SSAs, SSAs with dysplasia, TSAs and tubular adenomas failed to identify any CTNNB1 mutations to account for abnormal beta-catenin nuclear labeling.
|
19745699 |
2009 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Sequencing analyses identified APC or CTNNB1 mutations in the majority of sporadic adenomas (58/84, 69%) and MMR-proficient Lynch syndrome-associated adenomas (13/18, 72%).
|
28548127 |
2017 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Results suggest that modulation of aberrant beta-catenin expression occurs during NSAID-induced regression of intestinal adenomas and that Bcl-2 may confer resistance to these effects.
|
10223192 |
1999 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
LHGDN |
P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia.
|
12297840 |
2002 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Our purpose was the evaluation of microsatellite stability status within conventional colon adenomas and also β-catenin, BRAFV600E and p53 contribution.
|
28234922 |
2017 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Obese patients mainly develop inflammatory and β-catenin activated (highest risk for malignant transformation) adenomas.
|
27780309 |
2018 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Nuclear β-catenin labelings were significantly lower in the serrated series than in their adenoma counterparts, and a significant increment in those labelings was found from SSA/Ps to those with high-grade dysplasia or submucosal carcinoma.
|
24925057 |
2015 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Notably, nuclear accumulation of beta-catenin was observed only in adenomas and highly differentiated carcinomas with eosinophilic phenotype.
|
11280770 |
2001 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
No oncogenic beta-catenin mutations were identified in 34 MSI+ and 78 microsatellite stable (MSI-) sporadic colorectal cancers but a raised mutation frequency (8/44, 18.2%) was found in HNPCC cancers; this frequency was significantly higher than that in HNPCC adenomas (p=0.035) and in both MSI- (p<0.0001) and MSI+ (p=0.008) sporadic cancers.
|
15647192 |
2005 |
|
Adenoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
No mutations or deletions were seen in exon 3 of the beta-catenin gene for either the adenomas or the carcinoma.
|
18246041 |
2008 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Membraneous beta-catenin expression was significantly reduced in both FAP (30%; 11-49) and sporadic (42%; 19-65) adenomas (normal controls 96%; 88-104), whereas marked nuclear staining occurred in sporadic, but not in FAP adenomas.
|
14986031 |
2004 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Membrane beta-catenin expression was decreased in eight of 12 (66%) adenomas and in all 115 carcinomas (P: < 0.0001).
|
11238046 |
2001 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Likewise, the expression of β-catenin in severe dysplasia adenoma was 84.0 %, which was significantly higher than that in mild dysplasia adenoma (39.4 %).
|
24622886 |
2014 |
|
Adenoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Levels of β-catenin, cMyc, and ITF2 were increased in areas of human colon adenomas and carcinomas, compared with nontumor areas of the same tissues.
|
24846398 |
2014 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
It occurred at the transition to dysplasia in serrated polyps with a significant increase in nuclear β-catenin labeling from sessile serrated adenomas (10%) to sessile serrated adenomas with dysplasia (55%) and traditional serrated adenomas (9%) to traditional serrated adenomas with dysplasia (39%) (P=0.0001).
|
29148535 |
2018 |
|
Adenoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Increased cytoplasmic and/or nuclear beta-catenin staining was seen in 94% and 80% of the adenomas. beta-Catenin nuclear staining was strongly associated with MYC levels (p value 0.03) but not with KRAS mutations.Copy number aberrations were rare.
|
20196079 |
2010 |